We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Theranos' Woes May Reshape Private D&O Coverage

Law360, Los Angeles (October 19, 2016, 6:00 PM EDT) -- An investor's suit accusing Theranos Inc. of misrepresenting its blood-testing technologies and a U.S. Securities and Exchange Commission probe of the startup may lead insurers to broaden exclusions in directors and officers policies to reflect privately held firms' growing exposure to securities law claims, experts say.

In an Oct. 11 complaint filed in Delaware Chancery Court, hedge fund Partners Investments LP is seeking to rescind its agreement to purchase Theranos stock based on alleged misstatements made by the medical testing firm and its principals.

The suit,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.